{"": [115, 123, 0, 124, 1217, 0], "Introduction": [1218, 6381, 0], "Phage-display library construction and screening for isolation of anti-NTD antibodies": [6391, 10539, 0], "Anti-NTD antibodies specificity, affinity, and in\u00a0vitro neutralization potency": [10540, 11778, 0], "Epitope mapping and determining the involvement of S1-appended N-glycans": [11779, 18316, 0], "Addressing the neutralization mechanism of selected anti-NTD mAbs": [18317, 20812, 0], "Evaluating the therapeutic potential of anti-NTD mAbs in a SARS-CoV-2 lethal infection model": [20813, 24304, 0], "Endogenous humoral response to SARS CoV-2 of antibody-treated animals": [24305, 26017, 0], "Results": [6382, 26017, 1], "Limitations of the study": [36239, 36484, 0], "Discussion": [26018, 36484, 1], "Key resources table": [36499, 36524, 0], "Lead contact": [36548, 36768, 0], "Materials availability": [36769, 37047, 0], "Data and code availability": [37048, 37160, 0], "Resource availability": [36525, 37160, 1], "Human blood samples": [37202, 37975, 0], "Animals": [37976, 38637, 0], "Cells and virus strains": [38638, 40190, 0], "Bacterial strains": [40191, 40465, 0], "Experimental models and subject details": [37161, 40465, 1], "Recombinant proteins": [40482, 41715, 0], "Phage display libraries construction and selection": [41716, 45152, 0], "Single chain Fv individual clone characterization": [45153, 46103, 0], "Production of antibodies": [46104, 46991, 0], "ELISA": [46992, 49501, 0], "Biolayer interferometry assays": [49502, 51591, 0], "Epitope mapping": [51592, 52675, 0], "Glycan microarray fabrication": [52676, 53949, 0], "Sialoglycan microarray binding assay": [53950, 55799, 0], "Plaque reduction neutralization test (PRNT)": [55800, 57351, 0], "Animal experiments": [57352, 58425, 0], "Method details": [40466, 58425, 1], "Quantification and statistical analysis": [58426, 59497, 0], "STAR\u2605Methods": [36485, 59497, 1]}